Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

Multiple Myeloma Clinical Trial

Official title:

A Phase II Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00131261
• Other study ID #: PXD101-301-G
• Status: Completed
• Phase: Phase 2
• First received: August 17, 2005
• Last updated: July 7, 2015
• Start date: January 2005
• Est. completion date: June 2007

Study information

• Verified date: July 2015
• Source: Onxeo
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationNorway: Norwegian Medicines Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma. PXD101 is a new, potent histone deacetylase (HDAC) inhibitor. Various members of this class of drugs have shown activity in preclinical studies and in initial clinical trials of multiple myeloma and lymphoma. Furthermore, HDAC inhibitors, including PXD101, have been shown to sensitize myeloma cells to the killing effect of other chemotherapeutic agents, including dexamethasone, a well-established agent in relapsing myeloma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: June 2007
• Est. primary completion date: January 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion criteria

1. Signed informed consent

2. A confirmed diagnosis of multiple myeloma, diagnostic criteria as follows, in patients who have failed at least two prior lines of therapy.

Diagnostic criteria for multiple myeloma:

A Monoclonal immunoglobulin (M-component) in serum of IgG-type > 30 g/l, of IgA type > 20 g/l, of IgD type or IgE type of any concentration and/or excretion of M-component in the urine of type k or l type > 1 g/24 hours.

B M-component in serum and/or urine in lower concentration than indicated above in 'A'.

C 10% or more plasma cells in bone marrow aspirate or plasmocytosis in biopsy from bone marrow or soft tissue tumor D Osteolytical bone lesions.

The diagnosis of multiple myeloma demands one of the following combinations: A+C, A+D, or B+C+D.

3. Evaluable disease (as defined above)

4. Adequate bone marrow and hepatic functions including the following:

1. WBC > 2.5 x 109/l, absolute neutrophil count = 1.5 x 109/l, platelets = 50x109/l

2. Total bilirubin =1.5 x upper normal limit.

3. AST (SGOT), ALT (SGPT) =2.5 x upper normal limit

5. Serum potassium within normal range.

6. Age =18 years

7. Performance status (PS) =2 (ECOG scale)

8. Estimated life expectancy greater than 3 months

9. Female patients with reproductive potential with a negative serum pregnancy test within the last 7 days before trial enrollment and use a safe contraceptive during and in a period of 60 days after the trial. Fertile female partners to male participants must likewise use contraceptive.

Exclusion criteria

1. Anticancer therapy including chemotherapy, radiotherapy, endocrine therapy, immunotherapy or use of other investigational agents within the last 4 weeks or a longer period depending on the defined characteristics of the agents used (e.g. 6 weeks for mitomycin or nitrosourea). Exception: bisphosphonates for bone disease caused by multiple myeloma.

2. Active infection or any medical condition likely to interfere with trial procedures.

3. Significant cardiovascular disease including unstable angina pectoris, uncontrolled hypertension, congestive heart failure related to primary cardiac disease, a condition requiring anti-arrhythmic therapy, ischemic or severe valvular heart disease, or a myocardial infarction within 6 months prior to the trial entry.

4. A marked baseline prolongation of QT/QTc interval, e.g., repeated demonstration of a QTc interval >500; Long QT Syndrome; the required use of concomitant medication on PXD101 infusion days that may cause Torsade de Pointes. (See Appendix B for list).

5. Patients with renal insufficiency defined as a calculated creatinine clearance of < 45 ml/min.

6. Clinically significant central nervous system disorders requiring neuroleptics or anti-convulsant medication.

7. Altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies

8. Other malignant diseases requiring treatment

9. Non-secretory multiple myeloma or symptomatic amyloidosis

10. Pregnant or breast-feeding women

11. Women of childbearing age and potential, who do not use effective contraception

12. Known HIV positivity

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• PXD101

• Dexamethasone

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen
Norway	Research Facility	Bergen
Norway	Research Facility	Oslo
Norway	Research Facility	Trondheim
United Kingdom	Christie Hospital NHS Trust	Manchester
United Kingdom	The Royal Marsden NHS Trust	Surrey
United States	Northwestern University	Chicago	Illinois
United States	Research Facility	New York	New York
United States	H. Lee Moffitt Cancer Center	Tampa	Florida
United States	James Berenson, MD, Inc	West Hollywood	California

Sponsors (1)

Lead Sponsor	Collaborator
Onxeo

Countries where clinical trial is conducted

United States,  Denmark,  Norway,  United Kingdom,